ADORA2b, Alomone Labs, AAR-003

We found two peer-reviewed literature reports specifically describing the validation of AAR-003 from Alomone Labs. AAR-003 was validated for Western blotting by Bessa-Goncalves et al., Purinergic Signalling, 2023 entitled Blockage of the adenosine A2B receptor prevents cardiac fibroblasts overgrowth in rats with pulmonary arterial hypertension Two protein species were recognized by the A2BAR antibody corresponding to a peptide near the predicted molecular weight of the A2BAR (~37 kDa) and a higher molecular mass (~45 kDa) isotype. The naturally occurring A2BAR isotype is highly enriched in cardiac fibroblasts isolated from the right ventricle myocardium of MCT-treated rats compared to their control littermates. Both bands fully disappeared after pre-adsorption of the A2BAR primary antibody with a 10-fold molar excess of the A2BAR blocking peptide (#BLP-AR003, Alomone Labs) corresponding to amino acid residues 147–166 of the human A2BAR second extracellular loop (negative control). The rat urinary bladder (RB) was used as a positive control for the A2BAR, β-tubulin as loading control (Fig. 4C). WB dilution 1:200. https://link.springer.com/article/10.1007/s11302-023-09952-z AAR-003 was validated in IHC by Mikio Hayashi, IJMS, 2019, entitled Expression of Adenosine Receptors in Rodent Pancreas AAR-003 was used for IHC staining of paraffin sections. Validation/control was normal rabbit IgG isotype control; A2B staining was diminished in isotype-control panels across rat/mouse/guinea pig pancreas (Figures 1-4). Dilution 1:800 (Table 1). https://www.mdpi.com/1422-0067/20/21/5329 We have rated the antibody based on the available information and according to the pAbmAbs review criteria. We highly encourage other scientists to share their experience.